homepage-top-section

Characterised by recurrent inflammation of the skin associated with intense pruritus, AD is a non-contagious chronic, inflammatory disease of the skin. Almirall has submitted the application based on

Led by Canaan Ventures, the financing round has seen participation from Taiho Ventures, Osage University Partners, and Sanofi Ventures. Normunity intends to use the funds for advancing its

The regulator has accepted the company’ new drug application (NDA) for the combination therapy and as continuation of quizartinib monotherapy after consolidation to treat FLT3-ITD­–positive AML patients. Quizartinib,

If approved by the regulatory agency, neffy would be the first non-injectable treatment available to patients suffering with allergic reactions of Type I, including anaphylaxis. The regulatory body has

The platform of Refuge is a synthetic biology system leveraging an expression modulation strategy to repress or activate transcription of target genes. Early pre-clinical data indicate a potential

The regulator has recommended the radioligand therapy along with androgen deprivation therapy (ADT) with or without androgen receptor (AR) pathway inhibition to treat progressive PSMA- positive mCRPC adult

The companies will assess AdAlta’s CXCR4 inhibiting i-bodies as cancer therapeutics, using GPCR’s combination inhibition technique. AdAlta owns an i-bodies panel that inhibit CXCR4 signalling in different ways.

The company is seeking regulatory approval for SIS-101-ADO to treat Autosomal Dominant Osteopetrosis Type 2 (ADO2) patients. CSSi LifeSciences will be responsible for coordinating the regulatory process that

The CRISPR-based gene therapy has been indicated to treat Shiga-toxin producing bacterial infection to prevent hemolytic uremic syndrome (HUS). It has been designed to target Shiga toxins from